Global Chronic Obstructive Pulmonary Disease Drugs Market 2016-2020

SKU ID : TNV- 10279547

Publishing Date : 20-Jul-2016

No. of pages : 107


  • About Chronic Obstructive Pulmonary Disease (COPD)

    COPD is a chronic disease condition with a combination of symptoms of both chronic bronchitis and emphysema. Chronic bronchitis results in inflammation in the bronchioles, which results in increased mucus production. The condition is usually associated with a long-term cough with mucus. Emphysema results in the destruction of the walls of the alveoli, resulting in difficulty in breathing.

    Technavio’s analysts forecast the global chronic obstructive pulmonary disease (COPD) drugs market to grow at a CAGR of 4.85% during the period 2016-2020.

    Covered in this report
    The report covers the present scenario and the growth prospects of the global chronic obstructive pulmonary disease (COPD) drugs market for 2016-2020. To calculate the market size, the report considers the revenue generated from the sales of branded, generic, and off-label drugs used to treat COPD.

    The market is divided into the following segments based on geography:
    • Americas
    • APAC
    • EMEA

    Technavio's report, Global Chronic Obstructive Pulmonary Disease (COPD) Drugs Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

    Key vendors
    • AstraZeneca
    • Boehringer Ingelheim
    • GSK
    • Merck
    • Novartis
    • Teva

    Other prominent vendors
    • Ache Laboratorios Farmaceuticos
    • Almirall
    • Aquinox Pharmaceuticals
    • Ario Pharma
    • Asmacure
    • Astellas Pharma
    • BioMarck Pharmaceuticals
    • Chiesi Farmaceutici
    • Cytokinetics
    • F. Hoffmann-La Roche
    • Gilead Sciences
    • Innoviva
    • Invion
    • MediciNova
    • Mereo BioPharma
    • Mylan
    • Orion Corporation
    • Palobiofarma
    • Pearl Therapeutics
    • Pharmaxis
    • Prosonix
    • Pulmagen Therapeutics
    • RespiVert
    • SolAeroMed
    • Sunovion Pharmaceuticals
    • Theravance Biopharma
    • Theron Pharmaceuticals
    • Verona Pharma
    • Xention
    • Yungjin Pharm
    • ZAI Lab

    Market driver
    • Uptake of LABA/LAMA combination therapies
    • For a full, detailed list, view our report

    Market challenge
    • Negligence toward use of controller medications
    • For a full, detailed list, view our report

    Market trend
    • Increased adoption of e-cigarettes and smoking cessation products
    • For a full, detailed list, view our report

    Key questions answered in this report
    • What will the market size be in 2020 and what will the growth rate be?
    • What are the key market trends?
    • What is driving this market?
    • What are the challenges to market growth?
    • Who are the key vendors in this market space?
    • What are the market opportunities and threats faced by the key vendors?
    • What are the strengths and weaknesses of the key vendors?

    You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.

    Frequently Asked Questions

    This market study covers the global and regional market with an in-depth analysis of the overall growth prospects in the market. Furthermore, it sheds light on the comprehensive competitive landscape of the global market. The report further offers a dashboard overview of leading companies encompassing their successful marketing strategies, market contribution, recent developments in both historic and present contexts.

    • By product type
    • By End User/Applications
    • By Technology
    • By Region

    The report provides a detailed evaluation of the market by highlighting information on different aspects which include drivers, restraints, opportunities, and threats. This information can help stakeholders to make appropriate decisions before investing.
    market Reports market Reports